These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 37364775)
41. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918 [TBL] [Abstract][Full Text] [Related]
42. Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States. Ison MG; Marty FM; Chao N; Moon SH; Zhang Z; Chandak A Transpl Infect Dis; 2022 Aug; 24(4):e13866. PubMed ID: 35598293 [TBL] [Abstract][Full Text] [Related]
44. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis. Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301 [TBL] [Abstract][Full Text] [Related]
45. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation. Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226 [TBL] [Abstract][Full Text] [Related]
50. Increased Infections and Delayed CD4 Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754 [TBL] [Abstract][Full Text] [Related]
51. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Dignan FL; Potter MN; Ethell ME; Taylor M; Lewis L; Brennan J; McNamara L; Evans SO; Riley U; Davies FE; Dearden CE; Morgan GJ; Shaw BE Clin Transplant; 2013; 27(1):E56-63. PubMed ID: 23278853 [TBL] [Abstract][Full Text] [Related]
52. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039 [TBL] [Abstract][Full Text] [Related]
53. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation. Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288 [TBL] [Abstract][Full Text] [Related]
54. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799 [TBL] [Abstract][Full Text] [Related]
56. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation. Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587 [TBL] [Abstract][Full Text] [Related]
57. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514 [TBL] [Abstract][Full Text] [Related]
58. The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms. Nguyen CL; Docampo MD; van den Brink MR; Markey KA Curr Opin Genet Dev; 2021 Feb; 66():25-35. PubMed ID: 33388483 [TBL] [Abstract][Full Text] [Related]
59. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study. Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2022; 13():1066748. PubMed ID: 36685540 [TBL] [Abstract][Full Text] [Related]